Observational studyBMJ open respiratory research2022
Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates.
Observational study in BMJ open respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02755441 (Pulmonary Fibrosis Biomarker Cohort), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pulmonary Fibrosis Biomarker Cohort (PFBIO)
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review.BMJ open respiratory research · 2026Pooled it
- Association between body mass index and prognosis in interstitial lung disease: systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF).Advances in therapy · 2026Article
- Natural language processing-based intervention to detect interstitial lung abnormalities.The European respiratory journal · 2026Article
- Healthcare utilisation preceding the diagnosis of interstitial lung disease.ERJ open research · 2026Article
- Transbronchial lung cryobiopsy: a safe and effective technique in the diagnosis of interstitial lung disease in the older people.BMC geriatrics · 2026Observational
- Hospitalisations and idiopathic pulmonary fibrosis: lessons from two continents.ERJ open research · 2026Article
- Artificial Intelligence Enabled Lung Sound Auscultation in the Early Diagnosis and Subtyping of Interstitial Lung Disease.Journal of clinical medicine · 2025Review
- Article
- PET imaging of platelet derived growth factor receptor β in lung fibrosis.EJNMMI radiopharmacy and chemistry · 2025Article
- Evaluating the robustness of deep learning models trained to diagnose idiopathic pulmonary fibrosis using a retrospective study.Medical physics · 2025Article
- Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective.Respiratory research · 2025Review
- Progression of interstitial lung disease after the Envisia Genomic Classifier.ERJ open research · 2025Article
- Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry.BMJ open respiratory research · 2025Observational
- Predictive factors of fibrotic interstitial lung abnormality on high-resolution computed tomography scans: a prospective observational study.BMC pulmonary medicine · 2025Observational
- Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study.Pneumonia (Nathan Qld.) · 2025Article
- Traditional Herbal Plants and their Phytoconstituents Based Remedies for Respiratory Diseases: A Review.The open respiratory medicine journal · 2025Review
- Patient-centered care in pulmonary fibrosis: access, anticipate, and act.Respiratory research · 2024Review
- Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey.Respiratory research · 2024Article
- Proteomic signatures improve risk prediction for common and rare diseases.Nature medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of idiopathic pulmonary fibrosis (IPF) is often delayed up to several years. The objective of this study was to assess the impact of the diagnostic delay on progression-free survival, quality of life and hospitalisation rates.
methodsA total of 264 incident patients with IPF were included immediately after their diagnosis and followed for up to 5 years, with regular collection of clinical data, quality-of-life questionnaires and assessment of disease progression. Hospitalisation data were extracted from electronic patient records. Analyses were performed on the entire cohort and strata according to forced vital capacity (FVC) at diagnosis.
resultsA long diagnostic delay (>1 year) was associated with worse progression-free survival compared with a short diagnostic delay (<1 year) (HR: 1.70, 95% CI: 1.18 to 2.46, p=0.004) especially in patients with mild disease at the time of diagnosis (FVC>80% predicted). Mean total scores of the St. George's respiratory questionnaire (SGRQ), a derived IPF-specific version of the SGRQ and the chronic obstructive pulmonary disease assessment test (CAT) were consistently higher in patients with long diagnostic delays, indicating worse quality of life. Mean hospitalisation rates were higher during the first year after diagnosis (Incidence rate ratio [IRR]: 3.28, 95% CI: 1.35 to 8.55, p=0.01) and during the entire follow-up (IRR: 1.74, 95% CI: 1.01 to 3.02, p=0.04).
conclusionA diagnostic delay of more than 1 year negatively impacts progression-free survival, quality of life and hospitalisation rates in patients with IPF. These findings highlight the importance of an early diagnosis for proper management of IPF. TRIAL REGISTRATION NUMBER: NCT02755441.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.